TP53 and hematologic disorder: The silencing of SPAG6 has been demonstrated to inhibit the proliferation of malignant myeloid cell lines by activating tumor suppressor pathways, including p53, PTEN, and caspase-3/-8/-9, highlighting its potential as a prognostic factor in hematological malignancies [24].